Alector, Inc.
ALEC
NASDAQ·Healthcare·Biotechnology·Mkt cap $273.1M
$2.46
▼ -1.99%
P/E
-2.24
Mkt Cap
$273.1M
52-Wk Range
$1.09–$3.40
52-Week Range
$1.09 - $3.40
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 10.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Strategic partnership with GlaxoSmithKline for development and commercialization
- Advanced monoclonal antibody platform with multiple clinical-stage candidates
- Targeted approach to validated genetic risk factors in neurodegeneration
- Lead program (AL001) in Phase III trials with broad indication potential
Bear Case
1 risk
- Low volatility (beta 0.6).
Growth
Revenue decline expected
Phase III trial progression and potential regulatory approvals for AL001
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+50.0% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying ALEC right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 6, 2026
Reported EPS of -$0.21 vs -$0.23 consensus (+8.1% surprise). Revenue of $3.3M vs $1.7M expected (+93.8%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+8.1%
Revenue trend · last 8Q
—
+257%
-77%
-48%
-79%
-89%
-72%
-58%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$15.3M
$54.2M
$3.7M
$7.9M
$3.3M
$6.2M
$1.0M
$3.3M
Margins · last 8Q
Gross
0.0%
Operating
—
Profit
-692.5%
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Morgan Stanley · $2.00 · May 4, 2026
vs Industry
How ALEC stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related